AzTrials
AzTrials

Stroke, IschemicNCT07118345

Early Prophylactic Decompressive Hemicraniectomy Following Endovascular Therapy in Large Hemispheric Infarct Trial

A study testing Early prophylactic decompressive hemicraniectomy in people with Stroke, Ischemic and Cerebral Edema, run by Xuanwu Hospital, Beijing at 2 sites in China.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Early Decompressive Hemicraniectomy for High-Risk Large Ischemic Core Stroke Post-EVTAcute Ischemic Stroke (AIS), particularly Anterior Circulation Large Vessel Occlusion (LVO), is a major cause of global disability and death. Read more about this study

Who is it for?
Ages 18 to 75 years
Conditions the study is for
Stroke, Ischemic, Cerebral Edema
What is being tested?
Early prophylactic decompressive hemicraniectomy
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
380 participants
Where
2 sitesChina
Study dates
19 Jul 2025to 19 Jun 2029
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

None listed.

Who cannot join

  • Clinical Exclusion Criteria
  • Any symptoms and signs of brain herniation before randomization, such as pupil anisocoria and unstable vital signs.
  • In the judgment of the investigator, the subject is likely to have supportive care withdrawn in the first day.
  • Commitment to decompressive hemicraniectomy (DHC) prior to enrollment.
  • Severe, sustained hypertension (systolic blood pressure > 220 mm Hg or diastolic blood pressure > 110 mm Hg);
  • Baseline blood glucose <50 mg/dl (2.8 mmol/L) or >400 mg/dl (22.2 mmol/L);
Show all 20Show fewer
  • Baseline platelet count <100 x10^9/L;
  • Known hemorrhagic diathesis, coagulation factor deficiency, or oral anticoagulant therapy with international normalized ratio > 1.7;
  • Severe renal insufficiency, defined as serum creatinine > 3.0 mg/dl (or 265.2 μmol/l) or glomerular filtration rate [GFR] < 30 ml/min, or patients requiring hemodialysis or peritoneal dialysis;
  • Patients that cannot complete 90-day follow-up (such as no fixed residence, overseas patients, etc.);
  • Suspected vasculitis or septic embolism;
  • Neurological diseases or mental disorders before onset that affect the assessment of the condition;
  • Females who are pregnant or in lactation;
  • Participating in other clinical trials that could confound the evaluation of the study;
  • Subjects who, in the opinion of the investigator, have a life expectancy <3 months due to conditions not related to current LHI or are unlikely to comply with follow-up requirements. Other conditions that the investigators believe are not suitable for participation or may pose a significant risk to the patient.
  • Neuroimaging Exclusion Criteria
  • Evidence of other brain diseases such as cerebral trauma, intracranial tumor (except small meningioma), cerebral aneurysm, etc.
  • Evidence of acute ischemic infarction in bilateral anterior circulation territory or involvement of posterior circulation territories (other than in patients with a fetal or near-fetal PCA configuration);
  • Vascular perforation during thrombectomy;
  • The pre-randomization CT findings exhibits evidence of parenchymal hemorrhage 2 intracranial hemorrhage, diffuse severe subarachnoid hemorrhage, or intraventricular hemorrhage. Patients with localized mild subarachnoid hemorrhage, hemorrhagic infarction type1 or 2, and small parenchymal hematoma type 1 without midline shift may be included;

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

China2 sites, 2 recruiting
  • Xuanwu Hospital, Capital Medical University.

    Beijing

    Liqun Jiao, MD., 86+13911224991, jiaoliqun@xwhosp.org

    Not yet recruiting
  • Liaocheng Brain Hospital

    Shandong

    Liyong Zhang, MD., 86+13346256936, 13346256936@163.com

    Recruiting

Other trials in China

About this study

Early Decompressive Hemicraniectomy for High-Risk Large Ischemic Core Stroke Post-EVTAcute Ischemic Stroke (AIS), particularly Anterior Circulation Large Vessel Occlusion (LVO), is a major cause of global disability and death. While endovascular thrombectomy (EVT) is the standard first-line treatment for LVO, outcomes remain poor in patients with large ischemic cores (ASPECTS ≤5). Despite high recanalization rates (>90%), only 14-30% achieve functional independence (mRS 0-2) at 90 days, with 33-50% dead or severely disabled (mRS 5-6). Outcomes worsen dramatically with larger core volumes (e.g., only 4.4% functional independence with cores ≥150mL in SELECT2).A critical complication is Malignant Cerebral Edema (MCE), affecting ~50% of large-core patients post-EVT. MCE triggers a vicious cycle of rising intracranial pressure, reduced perfusion, and brain herniation. It drastically worsens prognosis: functional independence rates plummet (13.3% vs 51.2% without MCE), mortality significantly increases (OR=7.96, p=0.001), and functional outcomes deteriorate (OR=7.83, p=0.008). Strong predictors include low ASPECTS (<7) and large infarct volume.Decompressive Hemicraniectomy (DHC) is a life-saving intervention for MCE. Landmark trials (DESTINY, DECIMAL, HAMLET) and their meta-analysis show DHC within 24 hours in patients aged 18-60 significantly increases 12-month survival (78% vs 29%, ARR 50%) and rates of ambulatory independence (mRS ≤3: 43% vs 21%, ARR 23%). DESTINY II confirmed benefit in patients >60, improving functional outcomes (mRS 0-4: 38% vs 16%). Guidelines endorse DHC for large infarcts with deterioration.However, significant challenges persist:

DHC is Underutilized: Despite evidence, clinical adoption remains low.Rescue DHC Fails to Improve Outcomes in Post-EVT MCE: Studies report poor functional outcomes (only 20% mRS 0-2) and high mortality (48.6%) with standard medical therapy (SMT) plus rescue DHC after MCE develops. Retrospective data confirms worse outcomes in these patients (mRS 0-2: 16.4% vs 50%; mortality: 46.5% vs 20%) compared to those without MCE. Crucially, rescue DHC itself fails to improve prognosis once MCE is established (mRS 5-6: 64% vs 57.7%; mortality: 48% vs 46.2%).High-Risk Identification: Patients defined as high-risk for MCE (ASPECTS 3-5 + NIHSS≥30 or ASPECTS≤2) have significantly worse 90-day outcomes (mRS 0-2: 23.2% vs 44.6%; mortality: 44% vs 22.7%).Timing is Critical: Rescue DHC is often performed too late, after irreversible neurological damage occurs. Early/Prophylactic DHC, performed before significant edema and herniation develop, offers a potential pathophysiological advantage. It may:Improve cerebral perfusion pressure earlier. Reduce mass effect and edema progression. Mitigate secondary injury (e.g., reduce oxygen-free radicals, excitatory amino acids).Potentially break the ischemic-edema-herniation cycle sooner.Rationale for the Study: While DHC is effective for established MCE in non-EVT contexts and rescue DHC post-EVT is ineffective, high-quality evidence for early prophylactic DHC in high-risk large-core patients after successful EVT is lacking. Current guidelines do not address this specific, high-risk population where MCE incidence is ~50% and outcomes are dismal despite recanalization.

Study Aim: This trial will evaluate the efficacy and safety of early prophylactic decompressive hemicraniectomy compared to standard medical treatment (which includes rescue DHC if MCE develops) in AIS-LVO patients at high risk of MCE (defined by ASPECTS and NIHSS criteria) following successful EVT. The goal is to determine if proactive intervention can improve functional outcomes and reduce mortality in this critically ill population where current strategies fail.

Being tested
Early prophylactic decompressive hemicraniectomy
Keywords
Acute Ischemic Stroke, Endovascular Thrombectomy, Cerebral Edema, Hemicraniectomy
Medical subject headings
Ischemic Stroke, Brain Edema

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Early prophylactic decompressive hemicraniectomyProcedure or surgery

    Early prophylactic decompressive hemicraniectomy (decompressive hemicraniectomy is required to initiate within 6 hours after completion of mechanical thrombectomy and within 4 hours after randomization).

Study groups in NCT07118345
Study groupRoleWhat they receive
Experimental groupExperimentalEarly prophylactic decompressive hemicraniectomy
Receives: Procedure: Early prophylactic decompressive hemicraniectomy
Control groupNo interventionStandard medical treatment (with or without rescue decompressive craniectomy if needed).

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of mRS score of 0-4

    Rate of mRS score of 0-4

    Measured: 90 days (±7 days) after randomization

Secondary outcomes (16)
  1. Rate of mRS score of 0-3 Ordinal shift analysis of mRS •Rate of mRS score of 0-2 •Rate of midline shift ≥ 5 mm •Rate of brain herniation Improvement of the NIHSS Rate of neurological deterioration Rate of rescue decompressive hemicraniectomy

    mRS score ranges 0-6

    Measured: 90 days (±7 days) after randomization

  2. Ordinal shift analysis of mRS

    mRS score ranges 0-6

    Measured: 90 days (±7 days) after randomization

  3. Rate of mRS score of 0-2

    mRS score ranges 0-6

    Measured: 90 days (±7 days) after randomization

  4. Rate of midline shift ≥ 5 mm

    Based on imaging assessment (e.g., CT, MRI)

    Measured: Within 72 hours after randomization

  5. Rate of brain herniation

    e.g., 1 or 2 dilated, fixed pupils; unconsciousness related to edema [i.e., ≥2 on item 1a on the NIHSS]; and/or loss of other brain stem reflexes, attributable to edema or herniation according to the Investigator's judgment

    Measured: Within 72 hours after randomization

  6. Improvement of the NIHSS

    The NIHSS score range from 0 (no deficit) to 42 (maximum deficit)

    Measured: 5-7 days after randomization or discharge

  7. Rate of neurological deterioration

    Defined as increase of NIHSS score ≥4 from baseline

    Measured: 5-7 days after randomization or discharge

  8. Rate of rescue decompressive hemicraniectomy

    Control group

    Measured: 5-7 days after randomization or discharge

  9. Length of ICU stay

    Residual stay days of ICU

    Measured: Perioperative

  10. Length of hospitalization

    Residual stay days of hospitalization

    Measured: Perioperative

  11. Barthel Index

    The Barthel Index range from 0 (severe disability) to 100 (no disability)

    Measured: 90 days (±7 days) after randomization

  12. Modified Rankin scale and Barthel Index

    The mRS score range from 0 (no disability) to 6 (death), the Barthel Index range from 0 (severe disability) to 100 (no disability)

    Measured: 12 months (±30 days) after randomization

  13. Rate of any intracranial hemorrhage (ICH)

    The occurrence of ICH includes the following scenarios:

    1. new occurrence of ICH;
    2. progression of ICH based on Heidelberg Bleeding Classification.

    Measured: Within 72 hours after randomization

  14. Rate of parenchymal hematoma type 2 intracranial hemorrhage

    Measured: Within 72 hours after randomization

  15. Mortality

    Defined as mRS 6

    Measured: 90 days (±7 days) after randomization

  16. Serious Adverse Events

    Detailled description noted in study protocol

    Measured: 90 days (±7 days) after randomization

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Aug 2025
  2. Study start19 Jul 2025
  3. Primary completion19 Jun 2029 (estimated)
  4. Study completion19 Jun 2029 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
380 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07118345
Sponsor's protocol ID
IAT-EPIC
Status last verified
Aug 2025
First submitted
29 Jun 2025
Last updated
26 Jan 2026
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Early prophylactic decompressive hemicraniectomy in people with Stroke, Ischemic and Cerebral Edema, run by Xuanwu Hospital, Beijing at 2 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 0 inclusion and 20 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 26 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of mRS score of 0-4 (time frame: 90 days (±7 days) after randomization). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in